Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

News from Innoviva That We Consider Positively Impacting and Extremely Important
Innoviva, Inc. (INVA) (Innoviva), announced that the FDA Antmicrobial Drugs Advisory Committee (AMDAC) has unanimously voted 12-0 in favor of approval of sulbactam-durlobactam based on a favorable benefit-risk assessment for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.